Lymphoma
Rituximab + Lenalidomide vs Chemotherapy (RELEVANCE-7636)
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma. The "RELEVANCE" Trial (Rituximab Lenalidomide Versus Any Chemotherapy)
Investigator: Edward N. Libby, MD; Conditions: Follicular Lymphoma; Status: Recruiting; Study ID: NCT01476787
A Phase 1b, Single-Arm, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Pending; Study ID: NCT01644253
A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With Systemic Anaplastic Large Cell Lymphoma
Investigator: Andrei Shustov, M.D.; Conditions: Anaplastic Large-Cell Lymphoma; Status: Recruiting; Study ID: NCT01309789
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Investigator: Vivian Oehler, M.D,; Conditions: Hematologic Malignancies; Status: Closed; Study ID: NCT00953758
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Investigator: Andrei R. Shustov, MD; Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma; Status: Pending; Study ID: NCT01336933
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Investigator: Ajay K. Gopal, MD; Conditions: Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma; Status: Pending; Study ID: NCT01510184
A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy
Investigator: Andrei Shustov, MD; Conditions: Cutaneous T-cell Non-Hodgkin Lymphoma; Status: Recruiting; Study ID: NCT00958074
Phase II Trial Of Response-Adapted Chemotherapy Based On Positron Emission Tomography For Non-Bulky Stage I And II Hodgkin Lymphoma
Investigator: Fred Appelbaum, MD; Conditions: Hodgkin's Lymphoma; Status: Closed; Study ID: NCT01132807
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma
Investigator: Ann Woolfrey, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01193842
A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia
Investigator: Pamela S. Becker, MD; Conditions: Waldenstrom Macroglobulinemia; Status: Pending; Study ID: NCT01536067
Join Us On